• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

ORYX - Articles and news items


ORYX’s oncolytic parvovirus H1 successfully completes Phase I/IIa trial to treat glioblastoma multiforme

Industry news / 12 June 2015 / Victoria White

ORYX’s Phase I/IIa trial assessing oncolytic parvovirus H1 as a treatment for patients with glioblastoma multiforme has been successfully completed…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +